32 results
DEFA14A
VOR
Vor Biopharma Inc
2 May 24
Additional proxy soliciting materials
4:08pm
Exchange Act of 1934, as amended.
Dr. Namouni, 55, has served as President, Research and Development of Blueprint Medicines Corporation (“Blueprint
8-K
EX-99.1
VOR
Vor Biopharma Inc
2 May 24
Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors
4:07pm
of Fouad Namouni, M.D., to its Board of Directors. Dr. Namouni currently serves as President of Research & Development at Blueprint Medicines … research and development complements and strengthens the diverse perspectives on Vor’s Board and I look forward to working closely with him.”
Dr. Namouni
8-K
VOR
Vor Biopharma Inc
2 May 24
Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors
4:07pm
Committee of the Board (the “Nominating Committee”).
Dr. Namouni, 55, has served as President, Research and Development of Blueprint Medicines
424B5
9tgmlj788jr
23 Dec 22
Prospectus supplement for primary offering
4:05pm
424B5
ruqgra j39ar824q1s3o
8 Dec 22
Prospectus supplement for primary offering
5:15pm
S-3
oe24nux nk
14 Mar 22
Shelf registration
5:15pm
8-K
2rfko9r
17 Jun 21
Entry into a Material Definitive Agreement
8:13am
8-K
EX-99.1
f4rprpjnfunj440
17 Jun 21
Entry into a Material Definitive Agreement
8:13am
10-Q
xmvebqm5
6 May 21
Quarterly report
4:02pm